No clear answer
Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in relapsing and progressive MS
relapsing and progressive MS · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 2
These linked trials do not set the status.
- Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced SubjectsNo result found
Phase 1 · 2012 · Not randomised
- Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem CellsResult in a paper, not read yet
Phase not applicable · 2015 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as No clear answer
Related hypotheses
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in early MS (CIS or RIS)
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in primary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in relapsing MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in secondary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error